The first domestically produced recombinant shingles vaccine has been approved for clinical trials.

Herpes is caused by the reactivation of the chickenpox-shingherpes virus, usually manifests as a rash that appears to be painful and itchy on one side of the body.
people infected with the chickenpox-shinghers virus have a higher risk of shingles after infection, and age and decreased immune function are the main risk factors for shingles. Common complications
shingles include persistent post-shing herpes nerve pain (PHN, which occurs in up to 30% of cases of shingles), scarring, eye complications, secondary infections, and nerve paralysis.
phN patients were often associated with emotional, sleep and quality of life impairment, 45% of PHN patients with anxiety, depression, inattention and so on.
study reported that 60 percent of patients had or often had suicidal thoughts.
about 1.56 million new cases of shingles in China aged 50 and over each year.
older people and those with immunocompromised diseases are at highest risk of shingles.
more than 99% of people aged 50 and over have been infected with the chickenpox-shinghers virus.
estimate sized about a third of people will develop shingles in their lifetime.
people's risk of complications such as herpes and herpes after herpes increases after age 50.
about one-third of people will develop shingles in their lifetime, but about one in two people aged 85 and over will develop shingles.
two ribbon herpes vaccines are currently on the market worldwide, zostavax (live vaccine for shingles reduction) in Mershadon and Shingrix of GSK (recombinant shingles vaccine), which accounts for the majority of the market and has been approved for market in China.
the domestic development of shingles detoxification live vaccine manufacturers have Changchun Baike, Wantai Biology and Shanghai Institute of Biological Products, the development of recombinant shingles vaccine manufacturers are currently only Shanghai Yidao Biological and Jiangsu Zhonghui Yuantong.
.